Momtazi-Borojeni AA, Katsiki N, Pirro M, Banach M, Rasadi KA, Sahebkar A
Graphical Abstract Similar content being viewed by others Introduction Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) globally [1] and it poses a substantial burden on society and healthcare systems [2, 3]
Tirzepatide is actually a dual GIP/GLP-1 receptor agonist, working through two hormone pathways rather than just GLP-1
Gut Bacteroides species in health and disease
Long-term human safety data is still more limited than for well-established supplements like vitamin C, so periodic doctor check-ins are a reasonable precaution
Mounjaro: The branded, FDA-approved injectable tirzepatide, primarily for type 2 diabetes but often considered for weight management